Cecilia Brown

Lung Cancers Today

CheckMate 816 is now the &ldquo;only neoadjuvant-only immunotherapy phase 3 trial to demonstrate a statistically and clinically significant&rdquo; 5-year overall survival (OS) benefit for a resectable solid tumor, according to a presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.Patrick M. Forde, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.The combination of nivolumab plus chemotherapy is an &ldquo;established standard of care neoadjuvant treatment&rdquo; for eligible patients with resectable non-small cell lung cancer (NSCLC) and previously showed &ldquo;statistically significant and clinically meaningful improvements&rdquo; in event-free survival (EFS) and pathological complete response in the phase 3 CheckMate 816 study.At the 2025 ASCO Annual Meeting, Dr. Forde reported the planned final analysis of OS data from CheckMate 816 with 5 years of follow-up.The trial included adults with stage IB-IIIA resectable NSCLC, Eastern Cooperative Oncology Group performance status of &le; 1, and no known&nbsp;EGFR or ALK&nbsp;alterations. Patients were randomized 1:1 to receive neoadjuvant nivolumab plus chemotherapy Q3W or chemotherapy alone Q3W for three cycles, followed by surgery.The primary endpoints of CheckMate 816 were EFS and pCR, both assessed by blinded independent review. OS was a key prespecified, statistically powered secondary endpoint that was tested hierarchically, with exploratory analyses included for OS by ctDNA clearance and pCR status.<h2>CheckMate 816 Overall Survival Outcomes With Neoadjuvant Nivolumab plus Chemotherapy</h2>With a median follow-up of 68 months, the neoadjuvant nivolumab plus chemotherapy regimen demonstrated a statistically significant OS benefit compared with chemotherapy alone (median [95% CI], not reached [NR] versus 73.7 months [47.3&ndash;NR]; HR [95% CI], 0.72 [0.523&ndash;0.998];&nbsp;P =&nbsp;0.0479). The 5-year OS rate was 65% in those receiving the combination regimen, compared with 55% in those receiving chemotherapy alone. The OS &ldquo;favored&rdquo; the combination regimen in the subgroups of patients that were defined by tumor PD-L1 expression, baseline disease stage, and histology.An exploratory analysis of patients who were positive for ctDNA at baseline included 43 patients from each treatment group. The exploratory analysis showed that patients with presurgical ctDNA clearance, including 56% of those receiving the combination regimen and 35% of those receiving chemotherapy alone, had &ldquo;continued OS improvement&rdquo; compared with those without presurgical ctDNA across both treatment arms (HR [95% CI]: NIVO + chemo, 0.38 [0.15&ndash;1.00]; chemo, 0.39 [0.14&ndash;1.11]). Patients who achieved a complete pathologic response with nivolumab plus chemotherapy experienced &ldquo;sustained OS improvement&rdquo; compared to those who did not (HR [95% CI], 0.11 [0.04&ndash;0.36]), with 5-year OS rates of 95% versus 56%.In addition, neoadjuvant nivolumab plus chemotherapy continued to improve EFS compared with chemotherapy, showing a median EFS of 59.6 months (95% CI, 31.6&ndash;NR) compared with 21.1 months (95% CI, 16.5&ndash;36.8; HR [95% CI], 0.68 [0.51&ndash;0.91]). The five-year EFS rates were 49% in the group receiving the combination therapy versus 34% in those receiving chemotherapy alone. The researchers reported that &ldquo;no new safety signals were observed&rdquo; in this long-term follow-up analysis.Based on these findings, the study authors concluded that patients with a complete pathologic response to neoadjuvant nivolumab plus chemotherapy had a ~90% reduction in their risk of death by five years compared with those who did not have a complete pathologic response, and that these findings show a &ldquo;long-term survival benefit from a short course&rdquo; of neoadjuvant nivolumab plus chemotherapy and &ldquo;affirm a paradigm shift&rdquo; in the treatment of resectable NSCLC without actionable genomic alterations.
<div class="post-references"><h3>References</h3>Reference
2025 American Society of Clinical Oncology Meeting. Abstract <a href="https://www.asco.org/abstracts-presentations/ABSTRACT503132" target="_blank" rel="noopener">LBA8000</a>.
</div>

Cheryl Czerlanis, MD

ASCO 2025 Session Focuses on Expanding Access and Innovation in Lung Cancer Screening

ASCO 2025

CheckMate 816 Shows OS Benefit in Resectable NSCLC With 5-Year Follow-Up

Shriya Garg

Christopher Dee, MD

Laura Litwin

Research Shows Palliative Care Disparities Among Hispanic Patients With Lung Cancer

Helena Yu, MD

ASCO 2025: REZILIENT1 Insights From Dr. Helena Yu

Coral Olazagasti, MD

A Seat at the Table: Drs. Olazagasti, Velez Reflect on Research, Mentorship, and Collaboration at ASCO 2025

Phase 3 DeLLphi-304 Trial Shows Taralatamab Significantly Improves OS, PFS in Previously Treated SCLC

Latest News

The combination of nivolumab plus chemotherapy is an “established standard of care neoadjuvant treatment” for eligible patients with resectable non-small cell lung cancer (NSCLC).

ASCO 2025: CheckMate 816 Shows OS Benefit in Resectable NSCLC With 5-Year Follow-Up